GeoVax Advances Mpox Vaccine Development Amid WHO's Global Health Emergency Declaration

The World Health Organization's recent declaration of Mpox as a Public Health Emergency of International Concern (PHEIC) for the fourth time underscores the escalating threat posed by the Clade 1 strain of the Mpox virus. This strain, previously confined to Central Africa, has now been detected in Europe, Asia, and North America, including multiple U.S. states, signaling a potential for widespread transmission. The global reliance on a single manufacturer for the Mpox vaccine has raised concerns about biosecurity, affordability, and equitable distribution, especially as demand far exceeds current production capacity.

GeoVax Labs, Inc. is addressing this critical gap with its GEO-MVA vaccine, a U.S.-based alternative designed to enhance pandemic resilience. The company has completed cGMP drug substance manufacturing and is progressing towards clinical trials expected to begin in 2026. GEO-MVA's development utilizes an advanced continuous avian cell line manufacturing process, promising increased yield, scalability, and reduced dependency on traditional methods, thereby streamlining production and lowering costs.

The spread of Clade 1 Mpox and the limitations of the current vaccine supply chain highlight the urgent need for diversified and scalable solutions. GeoVax's efforts to align with U.S. federal initiatives for onshoring critical pharmaceutical manufacturing and strengthening national pandemic readiness reflect a proactive approach to mitigating future outbreaks. The company's engagement with policymakers to accelerate regulatory pathways and expand funding underscores the importance of innovation and collaboration in safeguarding public health against emerging infectious diseases.

The implications of GeoVax's advancements extend beyond immediate public health concerns, offering a blueprint for enhancing global vaccine equity and preparedness. As the Mpox situation evolves, the development of GEO-MVA represents a critical step towards reducing vulnerabilities in the global health infrastructure and ensuring a more resilient response to future pandemics.